{"id":"NCT04870606","sponsor":"Suzhou Kintor Pharmaceutical Inc,","briefTitle":"Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness","officialTitle":"A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Outpatients With Mild to Moderate COVID-19 Illness","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-03-05","primaryCompletion":"2022-01-24","completion":"2022-04-06","firstPosted":"2021-05-03","resultsPosted":"2024-01-02","lastUpdate":"2024-01-02"},"enrollment":733,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Efficacy and Safety"],"interventions":[{"type":"DRUG","name":"Proxalutamide (GT0918)","otherNames":["standard of care"]},{"type":"DRUG","name":"Placebo","otherNames":["standard of care"]}],"arms":[{"label":"GT0918+ standard of care","type":"ACTIVE_COMPARATOR"},{"label":"placebo+ standard of care","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the efficacy and safety of Proxalutamide (GT0918) as a treatment for outpatients COVID-19 subjects.","primaryOutcome":{"measure":"Efficacy in Terms of Clinical Status Following Treatment With Pruxelutamide (GT0918) Compared to Placebo","timeFrame":"28 days","effectByArm":[{"arm":"GT0918+ Standard of Care","deltaMin":361,"sd":null},{"arm":"Placebo+ Standard of Care","deltaMin":357,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":8,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":365},"commonTop":["Dizziness","Vertigo","Alanine aminotransferase increased","Blood creatine phosphokinase increased","Abdominal pain upper"]}}